"Nov. 19, 2012 -- Unemployment and a history of job loss may raise the risk for heart attack, a new study suggests.
The risk of heart attack may be highest during the first year of unemployment. And the more jobs a person loses, the hi"...
DOSAGE AND ADMINISTRATION
For intravenous infusion only.
Adenoscan (adenosine injection) should be given as a continuous peripheral intravenous infusion. The recommended intravenous dose for adults is 140 mcg/kg/min infused for six minutes (total dose of 0.84 mg/kg).
The required dose of thallium-201 should be injected at the midpoint of the Adenoscan (adenosine injection) infusion (i.e., after the first three minutes of Adenoscan (adenosine injection) ). Thallium-201 is physically compatible with Adenoscan (adenosine injection) and may be injected directly into the Adenoscan (adenosine injection) infusion set.
The injection should be as close to the venous access as possible to prevent an inadvertent increase in the dose of Adenoscan (adenosine injection) (the contents of the IV tubing) being administered.
There are no data on the safety or efficacy of alternative Adenoscan (adenosine injection) infusion protocols.
The safety and efficacy of Adenoscan (adenosine injection) administered by the intracoronary route have not been established.
The following Adenoscan (adenosine injection) infusion nomogram may be used to determine the appropriate infusion rate corrected for total body weight:
|Patient Weight||Infusion Rate mL/min|
This nomogram was derived from the following general formula:
0.140 (mg/kg/min) x total body weight (kg)/Adenoscan (adenosine injection) concentration (3 mg/ mL) = Infusion rate (mL/min)
Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
Adenoscan (adenosine injection) is supplied as 20 mL and 30 mL vials of sterile, nonpyrogenic solution in normal saline.
NDC 0469-0871-20 Product Code 87120
60 mg/20 mL (3 mg/mL) in a 20 mL single-dose, flip-top glass vial, packaged individually and in packages of ten.
NDC 0469-0871-30 Product Code 87130
90 mg/30 mL (3 mg/mL) in a 30 mL single-dose, flip-top glass vial, packaged individually and in packages of ten.
Store at controlled room temperature 15°-30°C (59°-86°F)
Do not refrigerate as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use. Contains no preservative. Discard unused portion.
Marketed by: Astellas Pharma US, Inc. Deerfield, IL 60015-2548. Manufactured by: Hospira, Inc. Lake Forest, IL 60045 USA. December 2010
Last reviewed on RxList: 4/7/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Adenoscan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.